Atypical neuroleptic malignant syndrome associated with iloperidone administration

Psychosomatics

Volumn 53, Issue 6, 2012, Pages 603-605

  Guanci, Nicole ^a   Aggarwal, Rashi ^a   Schleifer, Steven ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CREATINE KINASE; D DIMER; ESCITALOPRAM; ILOPERIDONE; LORAZEPAM; RISPERIDONE;

ADULT; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; CASE REPORT; CATATONIA; COMPUTER ASSISTED TOMOGRAPHY; DIAPHORESIS; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTENSIVE CARE; LETTER; LUNG EMBOLISM; MENTAL HEALTH; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; SCHIZOPHRENIA; TACHYCARDIA;

ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; ISOXAZOLES; NEUROLEPTIC MALIGNANT SYNDROME; PIPERIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 84875776285     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.06.011     Document Type: Letter

References (11)

1. Zarrouf F.A., Bhanot V. Neuroleptic malignant syndrome: don't let your guard down yet. Curr Psychiatry 2007, 6:89-95.
2. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialized second-generation antipsychotic. Int J Clin Practice 2009, 63:1237-1238.
3. Gurrera R.J., Caroff S.N., Cohen A., Carroll B.T., DeRoos F., Francis A., et al. An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method. J Clin Psychiatry 2011, 72:1222-1228.
4. Picard L.S., Lindsay S., Strawn J.R., Kaneria R.M., Patel N.C., Keck P.E. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008, 28:530-535.
5. Balzan M.V. The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity. Postgrad Med J 1998, 74:72-76.
6. Pope H.G., Keck P.E., McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a large Psychiatric hospital. Am J Psychiatry 1986, 143:1227-1233.
7. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatry 1985, 142:1137-1145.
8. Weder N.D., Muralee S., Penland H., Tampi R.R. Catatonia: a review. Ann Clin Psychiatry 2008, 20:97-107.
9. Sheil A.T., Collins K.A., Schandl C.A., Harley R.A. Fatal neurotoxic response to neuroleptic medications: a case report and review of the literature. Am J Forensic Med Pathol 2007, 28:116-120.
10. Mann S.C., Caroff S.N., Bleier H.R., Welz W.K., Kling M.A., Hayashida M. Lethal catatonia. Am J Psychiatry 1986, 143:1374-1380.
11. Mendhekar D.N., Jiloha R.C., Mehndiratta M.M., War L. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. Indian J Psychiatry 2002, 44:387-390.